Back to search
FDAFDA · Food and drugs·Recall number D-184-2013

HEXTEND 6% Hetastarch in Lactated Electrolyte Injection, 500 mL, Rx only , MANUFACTURED AND DISTRIBUTED BY HOSPIRA, INC., LAKE FOREST, IL 60045, NDC 0409-1555-54

Published March 13, 2013 · Recall initiated: October 22, 2012

Summary

FDA records drug Class II recall D-184-2013, published March 13, 2013 and initiated October 22, 2012. Recalling firm: Hospira Inc.; Status: Terminated; Reported quantity: 11,412 bags; Lot: Lot # 10-199-JT Exp. 10/13. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: There is the potential for the solution to leak from the seal of the fill tube to the bag.

What to do

Voluntary: Firm initiated · Letter

Get an email if HEXTEND has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
HEXTEND
Manufacturer
Hospira Inc.
Distributor
Nationwide
Lot
Lot # 10-199-JT Exp. 10/13
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was HEXTEND 6% Hetastarch in Lactated Electrolyte Injection, 500 mL, Rx only , MANUFACTURED AND DISTRIBUTED BY HOSPIRA, INC., LAKE FOREST, IL 60045, NDC 0409-1555-54 recalled?

Yes. FDA published recall D-184-2013 on March 13, 2013. Reported hazard: Lack of Assurance of Sterility: There is the potential for the solution to leak from the seal of the fill tube to the bag.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: HEXTEND.